ClinicalTrials.gg
CompletedNCT06579105SOLSTICEUpdated Jan 13, 2026

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

A Phase 2 interventional study of Placebo (placebo matching AZD5004 film-coated tablet) and AZD5004 in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 97 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
6th of 18
406 · median 57
Started
2024
with 4 others
Phase 2
Only one
of the 18
Registered
5th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 5 that started in 2024, is the only one in phase 2, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.

Read the detailed description

This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator. The study is planned to be conducted in approximately 15 countries, approximately 90 sites will be involved.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults ≥ 18 years of age.

Diagnosed with T2DM for at least 6 months.

≥ 7.0% and ≤ 10.5% managed with diet and exercise alone or with a stable dose of metformin or an SGLT2 inhibitor for at least one month prior to screening.

of ≥ 23 kg/m2.

Stable self-reported body weight for 3 months prior to randomization (+/- 5% body weight change).

Exclusion criteria

Exclusion Criteria:

Type 1 diabetes mellitus, secondary forms of diabetes or history of ketoacidosis or hyperosmolar coma.

History of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that required immediate treatment.

Have had more than one episode of severe hypoglycemia within 6 months prior to screening, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.

Received medication for weight loss within the last 3 months prior to screening.

inflammatory bowel disease, gastroparesis, severe disease or surgery affecting the upper GI tract.

Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier).

History of acute or chronic pancreatitis.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Experimental
    Arm 2

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Experimental
    Arm 3

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Experimental
    Arm 4

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Experimental
    Arm 5

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Experimental
    Arm 6

    Participants will receive xx mg once daily dose of AZD5004

    Drug: AZD5004

  • Active comparator
    Arm 7

    Participants will receive once daily dose of Semaglutide as active comparator

    Drug: Semaglutide

  • Placebo comparator
    Arm 8

    Participants will receive matching placebo for each AZD5004 arm

    Drug: Placebo (placebo matching AZD5004 film-coated tablet)

Interventions

  • DrugPlacebo (placebo matching AZD5004 film-coated tablet)

    Placebo film-coated tablet (matching AZD5004)

  • AZD5004 film-coated tablet, once daily during 26 weeks

  • 3-14 mg tablets of Semaglutide

    Also known as: Rybelsus

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    To evaluate the effect of AZD5004 versus placebo on glycemic control

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Change in fasting glucose

    To evaluate the effect of AZD5004 versus placebo on fasting glucose

    Time frame: Baseline to Weeks 4, 12, 16 and 26

  2. Achievement of HbA1c ≤ 6.5%

    To evaluate of the effect of AZD5004 versus placebo on HbA1c

    Time frame: Week 26

  3. Baseline HbA1c ≥ 7.0% and achieved HbA1c < 7.0%

    To evaluate the effect of AZD5004 versus placebo on HbA1c

    Time frame: Week 26

  4. Percent change in body weight

    To evaluate the effect of AZD5004 versus placebo on weight loss

    Time frame: Baseline to Week 26

  5. Absolute change in body weight

    To evaluate the effect of AZD5004 versus placebo on weight loss

    Time frame: Baseline to Week 26

  6. Achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight reduction

    To evaluate the effect of AZD5004 versus placebo on weight loss

    Time frame: Baseline to Week 26

07

Study locations

97 sites
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Sheffield, Alabama 35660, United States
  • Research Site
    Vestavia Hills, Alabama 35216, United States
  • Research Site
    Tucson, Arizona 85710, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Long Beach, California 90815, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Newport Beach, California 92660, United States
  • Research Site
    Sacramento, California 95821, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Lake City, Florida 32055, United States
  • Research Site
    Largo, Florida 33777, United States
  • Research Site
    Ocoee, Florida 34761, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Lombard, Illinois 60148, United States
  • Research Site
    Potomac, Maryland 20854, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Roslindale, Massachusetts 02131, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Gulfport, Mississippi 39503, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    Albuquerque, New Mexico 87107, United States
  • Research Site
    Binghamton, New York 13905, United States
  • Research Site
    Durham, North Carolina 27701, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Rocky Mount, North Carolina 27804, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    Beachwood, Ohio 44122, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    West Chester, Pennsylvania 19380, United States
  • Research Site
    Gaffney, South Carolina 29340, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Abilene, Texas 79606, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    West Jordan, Utah 84088, United States
  • Research Site
    Charlottesville, Virginia 22911, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Norfolk, Virginia 23504, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Kingwood, West Virginia 26537, United States
  • Research Site
    Surrey, British Columbia V3T 2V6, Canada
  • Research Site
    Brampton, Ontario L6T 0G1, Canada
  • Research Site
    Burlington, Ontario L7M 4Y1, Canada
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Lévis, Quebec G6V 6E2, Canada
  • Research Site
    Falkensee, 14612, Germany
  • Research Site
    Hamburg, 22607, Germany
  • Research Site
    Münster, 48145, Germany
  • Research Site
    Oldenburg, 23758, Germany
  • Research Site
    Sankt Ingbert, 66386, Germany
  • Research Site
    Wangen, 88239, Germany
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Chūōku, 103-0027, Japan
  • Research Site
    Chūōku, 104-0031, Japan
  • Research Site
    Matsuyama, 7900034, Japan
  • Research Site
    Shinjuku-ku, 160-0008, Japan
  • Research Site
    Bialystok, 15-435, Poland
  • Research Site
    Krakow, 31-156, Poland
  • Research Site
    Krakow, 31-261, Poland
  • Research Site
    Lodz, 90-338, Poland
  • Research Site
    Lublin, 20-718, Poland
  • Research Site
    Poznan, 60-589, Poland
  • Research Site
    Poznan, 61-655, Poland
  • Research Site
    Tarnów, 33-100, Poland
  • Research Site
    Bratislava, 831 03, Slovakia
  • Research Site
    Prešov, 080 01, Slovakia
  • Research Site
    Rožňava, 048 01, Slovakia
  • Research Site
    Sabinov, 083 01, Slovakia
  • Research Site
    Trebišov, 07501, Slovakia
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28006, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Seville, 41003, Spain
  • Research Site
    Seville, 41010, Spain
  • Research Site
    Seville, 41950, Spain
  • Research Site
    Blackpool, FY3 7EN, United Kingdom
  • Research Site
    Bristol, BS34 6BQ, United Kingdom
  • Research Site
    Chesterfield, S40 4AA, United Kingdom
  • Research Site
    Corby, NN17 2UR, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Rotherham, S65 1DA, United Kingdom
  • Research Site
    Yate, BS37 4AX, United Kingdom
08

References and documents

Publications

  • Aroda VR, Davies MJ, Maaske J, Millegard M, Juan VL, Aberle J, Ciudin A, McCrimmon RJ, Eklund O, Shih JL, Sjostrand M, Zarzuela D, Rosenstock J. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. Lancet. 2026 Jun 20;407(10547):2515-2527. doi: 10.1016/S0140-6736(26)00802-0. Epub 2026 Jun 8. PubMed 42259343 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 14 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Oct 8, 2024
Primary completionActual
Dec 19, 2025
CompletionActual
Dec 19, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579105
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Oct 8, 2024
Primary completion
Dec 19, 2025
Completion
Dec 19, 2025
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion